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Abstract Until now, more than 800 distinct G protein-
coupled receptors (GPCRs) have been identified in the
human genome. The four subtypes of the adenosine
receptor (A1,A 2A,A 2B and A3 receptor) belong to this
large family of GPCRs that represent the most widely
targeted pharmacological protein class. Since adenosine
receptors are widespread throughout the body and involved
in a variety of physiological processes and diseases, there is
great interest in understanding how the different subtypes
are regulated, as a basis for designing therapeutic drugs that
either avoid or make use of this regulation. The major
GPCR regulatory pathway involves phosphorylation of
activated receptors by G protein-coupled receptor kinases
(GRKs), a process that is followed by binding of arrestin
proteins. This prevents receptors from activating down-
stream heterotrimeric G protein pathways, but at the same
time allows activation of arrestin-dependent signalling
pathways. Upon agonist treatment, adenosine receptor
subtypes are differently regulated. For instance, the A1Rs
are not (readily) phosphorylated and internalize slowly,
showing a typical half-life of several hours, whereas the
A2AR and A2BR undergo much faster downregulation,
usually shorter than 1 h. The A3R is subject to even faster
downregulation, often a matter of minutes. The fast
desensitization of the A3R after agonist exposure may be
therapeutically equivalent to antagonist occupancy of the
receptor. This review describes the process of desensitiza-
tion and internalization of the different adenosine subtypes
in cell systems, tissues and in vivo studies. In addition,
molecular mechanisms involved in adenosine receptor
desensitization are discussed.
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Introduction
Adenosine is an important neuromodulator involved in a
variety of brain activities and it also serves many different
functions in the periphery. This nucleoside, when extracel-
lular, exerts its action via specific G protein-coupled
receptors (GPCRs) of the P1 class, divided into four
subtypes: A1R, A2AR, A2BR and A3R[ 1]. GPCRs consist
of a single polypeptide, containing seven α-helices which
are oriented perpendicular to the membrane. The N
terminus is located at the extracellular side of the cell and
often contains one or more glycosylation sites. The C
terminus is located intracellularly and contains phosphory-
lation and palmitoylation sites, which are involved in
regulation of receptor desensitization and internalization
[2]. All adenosine receptors, with the exception of the
A2AR, contain a palmitoylation site near the C terminus.
The A2AR is the only subtype with an extraordinary long C
terminus, 122 amino acids versus 36 amino acids in e.g. the
A1R[ 3]. All the adenosine receptors are glycosylated on
the second extracellular loop, although glycosylation does
not appear to influence ligand binding. The third intracel-
lular loop and/or the C terminus are involved in coupling
the adenosine receptors to G proteins. Phosphorylation of in
particular intracellular loop 3 is involved in desensitization
and internalization of adenosine receptors [4–6].
Adenosine and analogues
Adenosine, consisting of a purine ring connected to a ribose
group, is the endogenous ligand for the adenosine receptors
(Fig. 1). Under normal conditions, adenosine is continu-
ously formed extracellularly by dephosphorylation of ATP,
ADP and/or AMP to adenosine by NTPDases (ectonucleo-
side triphosphate diphosphohydrolases). However, the A3R
can also be activated by inosine, a breakdown product from
adenosine [5]. Most adenosine receptor agonists are
analogues of adenosine, modified by N
6, C2 and C8
substitutions at the adenine base, and C5′ modifications of
the ribose moiety [5, 6]. Antagonists lack the ribose group
and usually possess a mono-, bi- or tricyclic core structure,
e.g. caffeïne, which contains a xanthine as basic structure
(Fig. 1). For extended reviews on high affinity agonists and
antagonists for adenosine receptors and their structure-
activity relationships, see Palmer and Stiles [1], Fredholm
et al. [5], Jacobson and Gao [7], Beukers et al. [8], Müller
[9] and Klotz [10].
Occurrence and physiological functions of adenosine
receptors
The adenosine receptors are widespread throughout the
body and exert many different functions both in the CNS
and in the periphery.
The A1R is particularly prevalent in the central nervous
system, with high levels in the cerebral cortex, hippocam-
pus, cerebellum, thalamus, brain stem and spinal cord.
Numerous peripheral tissues also express the A1R, includ-
ing vas deferens, testis, white adipose tissue, stomach,
spleen, pituitary, adrenal gland, heart, aorta, liver, eye and
bladder. Low levels are found in the lung, kidney and small
intestine [1, 5, 6]. The A1R is involved in cardiovascular
effects (e.g. reducing heart rate), inhibition of lipolysis and
stimulation of glucose uptake in white adipocytes and the
modulation of neurotransmitter release in the CNS [1]. The
A1R also plays a role in anxiety, hyperalgesia, broncho-
constriction and the glomerular filtration rate and renin
release in the kidney [5, 6, 11].
In the CNS, the A2AR is highly expressed in the striatum
and olfactory tubercle [1]. In the periphery, it is highly
expressed in the spleen, thymus, leucocytes and blood
platelets, and intermediate levels are found in the heart,
lung and blood vessels [5, 6]. The A2AR is involved in the
onset of vasodilation, inhibition of platelet aggregation,
exploratory activity, aggressiveness and hypoalgesia [1].
In addition, A2AR plays a role in Parkinson’s disease,
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Fig. 1 Chemical structures of the endogenous ligand adenosine and
the antagonist caffeine
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attenuation of inflammation and neuroprotection, particu-
larly in peripheral tissues [5, 6]. A2A receptor antagonists
slow the neurodegeneration which occurs in Parkinson’s
and Huntington’s disease and also prevent toxicity induced
by beta-amyloid in the development of Alzheimer’s disease
[12–14].
The A2BR is widely expressed in the brain, but generally
at very low levels. In the periphery, high levels of A2BR
were detected in the caecum, large intestine and urinary
bladder. Lower levels were observed in the lung, spinal
cord, vas deferens, pituitary, adipose tissue, adrenal gland,
kidney, liver and ovaries [5, 6]. Since there is a lack of
specific agonists for the A2BR, little is known about the
functional significance of this receptor. However, the A2BR
plays a role in mediating vasodilation in a.o. the aorta, the
renal artery and the coronary artery of different species. It is
also involved in allergic and inflammatory disorders [5, 6].
The A3R is expressed in the CNS, but at relatively low
levels, and only the hypothalamus and the thalamus have
been reported to contain A3R[ 15]. The highest levels of
adenosine A3R have been found in the lung and liver, and
somewhat lower levels were found in the aorta [1]. In
addition, the A3R was found in eosinophils, mast cells,
testis, kidney, placenta, heart, spleen, uterus, bladder,
jejunum, aorta, proximal colon and eye, although with
pronounced differences in expression level between species
[5, 6, 16]. The A3R has been implicated in mediating
allergic responses, airway inflammation and apoptotic
events; however, the latter is dependent on the cell type
involved and/or the type of activation [5, 16]. Furthermore,
the A3R is involved in the control of the cell cycle and
inhibition of tumour growth both in vitro and in vivo [6]. In
fact, adenosine A3 receptors have been demonstrated to be
more highly expressed in tumours than in healthy cells,
suggesting a role for A3R as a tumour marker [17].
Signal transduction of adenosine receptors
G protein-coupling and second messengers
Heterotrimeric G proteins are guanine-nucleotide regulatory
protein complexes composed of α and βγ subunits. They
are responsible for transmitting signals from G protein-
coupled receptors to effectors, e.g. adenylyl cyclase. Until
now, 16 α,5β and 14 γ isoforms have been reported [18].
G proteins are divided into several subclasses with a
specific activity profile: Gs proteins stimulate adenylyl
cyclase, Gi proteins inhibit adenylyl cyclase and stimulate
GIRK channels, G0 proteins stimulate K
+ ion channels, Gq/11
proteins activate phospholipase C, G12 proteins activate Rho
guanine-nucleotide exchange factors (GEFs) and the olfac-
tory G protein, Golf, stimulates adenylyl cyclase. Upon
receptor activation, both the α subunit and the βγ subunit
can signal, but to different effectors [19–21]. For a recent
review on G proteins, see Milligan and Kostenis [18].
The A1R is usually coupled to a pertussis toxin-sensitive
Gia protein, which mediates inhibition of adenylyl cyclase
and regulates calcium and potassium channels [1, 3, 5, 6,
11]. Both the third intracellular loop and the C-terminal tail
of the A1R are involved in Gia coupling [5]. In addition, it
has been reported that under certain conditions the A1R
couples to Gs to stimulate adenylyl cyclase, or to Gq/11 to
stimulate inositol phosphate production. Apparently, the
specific activity state of the receptor or the nature of the
agonist determine which G protein class is activated by
the A1R[ 22, 23]. The A2AR in the periphery is coupled to
cholera toxin-sensitive Gsa proteins, which increase
adenylyl cyclase activity upon receptor activation. The
A2AR in the striatum is presumably coupled to Golf [5, 6].
The third intracellular loop, but not the C terminus of the
A2AR, is involved in Gsa coupling [5]. The A2BRi sc o u p l e d
to Gsa proteins leading to stimulation of adenylyl cyclase
upon receptor activation [6]. There is quite some evidence
that A2BR can activate phospholipase C as well, via Gq/11
proteins [5]. The A3R is coupled to pertussis toxin-sensitive
Gia proteins, which mediate inhibition of adenylyl cyclase.
In addition, A3R can stimulate phospholipase C via Gq/11
proteins [5, 6]. For an extensive overview of adenosine
receptor-G protein coupling, see Fredholm et al. [24].
Desensitization and internalization—general principles
and players
Mechanisms to dampen GPCR signalling exist at every
level in the cell. In this section attention will be paid to the
underlying principles of desensitization and internalization
and the protein partners involved in these processes.
Receptor localization
Depending on the localization signal, GPCRs in the plasma
membrane can be targeted to lipid rafts
1 or caveolae
2.
1 Lipid rafts are planar domains of 25–100 nm in cell membranes
enriched in specific lipids and proteins. They are in particular
characterised by a high cholesterol and glycosphingolipid content in
the outer leaflet of the lipid bilayer that gives them a gel-like liquid-
ordered organization in comparison with the surrounding phospholipid-
rich disordered membrane [26].
2 Caveolae are flask-shaped invaginations located at or near the
plasma membrane with a 50–100 nm diameter. They are considered to
be a non-planar subfamily of lipid rafts. The shape and structural
organization of caveolae are due to the presence of caveolin−1, −2 and
−3, which self-assemble in high-mass oligomers to form a cytoplasmic
coat on the membrane invaginations [25, 26].
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targeting to either lipid rafts or caveolae but may also
enable an interaction of the receptor with constituents of
these rafts and caveolae. For instance the extracellular part
of the receptor might interact with GM1 gangliosides
(glycosphingolipids) present in lipid rafts/caveolae. In
addition, the C-terminal fatty acid acylation or palmitoyla-
tion may also affect targeting of GPCRs to either lipid rafts
or caveolae. Finally, transmembrane regions may interact
with cholesterol in the lipid rafts resulting in a change in
conformation of the α-helices. Since the conformation of
α-helices depends on the activation state of GPCRs, it may
well be that agonist binding to the receptor may affect its
localization in lipid rafts by means of molecular transitions
leading to receptor activation [25, 26].
Desensitization
Desensitization reduces receptor activity and plays a role in
signal duration, intensity and quality. Desensitization is
initiated by phosphorylation of serine and/or threonine
residues in the third intracellular loop and C terminus of the
receptor. Two types of desensitization occur, heterologous
and homologous desensitization, and both are the result of
receptor phosphorylation. Heterologous desensitization is
induced by phosphorylation of the receptor by protein
kinase A or C—sometimes even without agonist occupan-
cy. On the other hand, homologous desensitization is
specific for agonist-occupied receptors and consists in most
cases of two steps. First, the receptor is phosphorylated by
one of the G protein-coupled receptor kinases (GRKs 1-7);
then it binds to β-arrestin, of which two subtypes exist,
which exhibit high affinity for agonist-occupied, phosphor-
ylated receptors. β-Arrestin serves to sterically inhibit G
protein coupling, thereby terminating the G protein activa-
tion, and may also target the receptor to clathrin-coated
pits
3 for internalization (Fig. 2)[ 19, 25, 27, 28].
Fig. 2 Homologous (a)a n d
heterologous (b) desensitization
and subsequent internalization
of GPCRs. a ¼ Gia subunit,
βg ¼ Giβg subunit, L ligand,
GRK G protein-coupled receptor
kinase, P phosphorylated amino
acids, β-arr β-arrestin, AP2
adaptin, E effector, second
messenger, PKA protein kinase
A, PKC protein kinase C
3 Clathrin-coated pit is a specialized region of the cell surface that
mediates the internalization of extracellular macromolecules and
GPCRs. Coated pits derive their name from the presence of a
distinctive polygonal lattice that decorates the inner surface of the
membrane. This lattice is composed of multiple triskelion-shaped
subunits that contain three clathrin heavy chains (180 kD) and three
clathrin light chains (30–40 kD) plus a family of associated proteins
with molecular sizes of 50 kD and 110 kD [29, 30].
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Receptor desensitization, initiated by phosphorylation of
the receptor by different protein kinases (A or C) or GRKs,
can be subsequently followed by receptor internalization.
Upon phosphorylation, β-arrestin 1 or 2 is attracted to the
receptor [31]. β-Arrestins not only interact with the
phosphorylated receptor, but also bind to the heavy chain
of clathrin, to the β2-adaptin subunit of the clathrin adaptor
protein AP2, and to phosphoinositides. These interactions
direct the phosphorylated receptor to punctate clathrin-
coated pits in the cell membrane, which are internalized by
action of the GTPase dynamin. Upon internalization,
receptors can either be rapidly recycled to the plasma
membrane, targeted to larger endosomes and slowly
recycled, or degraded in lysosomes. The final destination
of the internalized receptors largely depends on the β-
arrestin subtype (1 or 2) that is recruited by the receptor
upon phosphorylation and the duration of β-arrestin
binding. In this way, internalization may regulate receptor
resensitization and contributes to a positive regulation of
receptor signalling [19, 25, 31].
Internalization pathways
From internalization studies with several receptors, it
appears that the internalization pathway is specific for
receptor type, cell type, metabolic state of the cell, cell-
specific factors etc. Receptor trafficking can be regulated in
different ways (Fig. 3): (a) the receptor resides mainly in
lipid rafts/caveolae and enters the cell via this pathway by
default; (b) the receptor is in lipid rafts, but leaves these
upon agonist binding to be internalized via clathrin-coated
pits; (c) the receptor moves into lipid rafts upon agonist
binding and is internalized via this pathway; (d) the
receptor moves into lipid rafts after agonist binding to
activate certain signalling events, but is eventually moved
out of the lipid rafts to be internalized via clathrin-coated
pits. Internalization can even be achieved via uncoated
vesicles or by a combination of two or more of the
aforementioned pathways. For example, β1-AR is internal-
ized via both lipid rafts and clathrin-coated pits. PKA
phosphorylation directs β1-AR to a clathrin-coated pit,
whereas GRK phosphorylation directs the receptor to lipid
raft-mediated internalization [19, 25, 26].
Function of lipid rafts/caveolae
The existence of lipid rafts/caveolae serves different
functions. First of all, lipid rafts act as ‘stations’ in which
GPCRs accomplish specific signalling tasks by meeting a
selected set of signalling molecules, e.g. G proteins and
adenylyl cyclases. Another possible function of lipid rafts is
the protection of receptors from rapid constitutive or
agonist-induced internalization, thus allowing their cou-
pling to specific signalling pathways. In addition, caveolin
may regulate the constitutive activity of receptors [32].
Finally, the endocytic pathways that GPCRs choose may
Fig. 3 Different
internalization pathways, adap-
ted from Chini and Parenti,
2004 [25]. Internalization via (a)
lipid rafts/caveolae, (b) upon
agonist binding, the receptor
moves to clathrin-coated pits to
be internalized, (c) the receptor
moves into lipid rafts upon
agonist binding and is internal-
ized, (d) the receptor moves into
lipid rafts upon agonist binding
to activate certain signalling
events, but is eventually moved
out to be internalized via
clathrin-coated pits. Ligand (L,
green triangle), clathrin-coated
pits (dotted blue lines) and lipid
rafts (solid pink lines) are
indicated
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tion pathway from lipid rafts/caveolae to clathrin-coated
pits may alter the final receptor destination [19, 25, 26].
Research on adenosine receptors probably provided the
first account of receptor internalization via caveolae and
lipid rafts, as an alternative to the well-described β-arrestin
pathway [33].
G protein-coupled receptor kinases (GRKs)
Upon agonist binding to GPCRs, not only G proteins are
recruited to the activated receptor conformation, but also
two other protein families, namely the G protein-coupled
receptor kinases (GRKs) and the β-arrestins [31]. The GRK
family consists of seven different genes. The GRKs have
been divided into three protein subfamilies, based on
sequence similarity. GRK1 and GRK7 belong together.
The second subfamily consists of GRK2 and GRK3 since
their membrane recruitment depends on interaction with
Gβγ subunits and phosphatidylinositol 4,5-bisphosphate.
GRK2 and GRK3 are primarily responsible for agonist-
dependent receptor phosphorylation, β-arrestin recruitment
and functional uncoupling of the receptor. GRK4, GRK5
and GRK6 form the third subfamily and are constitutively
associated with the membrane. GRK1 and GRK7 are ex-
pressed mainly in the retinal rods and cones, whereas GRK4
expression is limited to the cerebellum, testis and kidney. In
contrast, GRK2, GRK3, GRK5 and GRK6 are widely ex-
pressed in mammalian tissues [31].
β-Arrestins
β-Arrestins belong to the arrestin family of which four
members have been identified. Arrestin 1 and arrestin 4 are
expressed in the visual system in retinal photoreceptor cells;
arrestin 2 (also called β-arrestin 1) and arrestin 3 (also
called β-arrestin 2) are more widely expressed and are
involved in the regulation of nonvisual GPCRs. The β-
arrestins were originally discovered as molecules that bind
to and desensitize the activated and phosphorylated form of
G protein-coupled receptors as described before [19, 25, 27,
28, 31]. The β-arrestin protein consists of an N and a C
domain, which are almost entirely composed of antiparallel
β sheets, connected by a linker of 12 amino acids. A ‘polar
core’ is embedded between those two domains, and its
disruption by the phosphorylated C terminus of the
activated receptor leads to conformational changes in the
β-arrestin. The C tail of the β-arrestin is then released,
exposing both the clathrin and the AP2 binding domains.
Recently, it appeared that β-arrestins not only are involved
in the desensitization of G protein-coupled receptors, but
also act as signal transducers on their own. As a
consequence, they emerge as multifunctional adaptor/
scaffold proteins which mediate cellular processes such as
chemotaxis, apoptosis and metastasis besides receptor
signalling and trafficking. For an extensive and recent
review on the interactions of β-arrestins with other cellular
proteins, see Lefkowitz et al. [34].
GRKs and β-arrestins orchestrate GPCR activities at
three different levels: (1) silencing: the functional uncou-
pling of the receptor from its G protein by a mechanism
known as ‘homologous desensitization’, (2) trafficking,
which involves receptor internalization, resensitization and/
or degradation, and (3) cross-signalling: activation or
inhibition of intracellular signalling pathways, independent
of heterotrimeric G proteins [31].
Dampening adenosine receptor signals
In this section we will discuss the evidence for and
mechanisms of desensitization and internalization of the
four adenosine receptor subtypes. For each receptor we will
first summarize results from in vitro, ex vivo and in vivo
studies. This will be followed by a more biochemical
approach in which we will focus on the molecular
mechanisms of adenosine receptor desensitization and
internalization by paying attention to the role of accessory
proteins, the influence of receptor mutations, etc. We will
refer to earlier seminal publications, but mostly focus on
more recent evidence for adenosine receptor desensitization
and internalization.
A1 receptor
Cellular and physiological studies
The early evidence for adenosine A1 receptor desensitiza-
tion was largely obtained from primary cells, cell lines,
tissues or tissue slices, and intact animals that were exposed
to varying concentrations of adenosine receptor agonists
(either A1-selective or not), often examined over several
time periods.
Stiles and co-workers were among the first to study A1
receptor desensitization in detail (1991). Ramkumar et al.
pretreated DDT1 MF-2 cells, a smooth muscle cell line
expressing both A1 and A2A receptors, with R-phenyl-
isopropyl adenosine (R-PIA) for up to 24 h, after which the
adenylyl cyclase activity was reduced by approximately
50%. This was associated with a significant decrease in cell
membrane-bound A1 receptors and a concomitant increase
of receptor number in intracellular compartments. The
authors also showed an increase in receptor phosphoryla-
tion, nicely paralleling the time course of adenylyl cyclase
modulation [35]. In a later study, Nie et al. reported similar
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occurred at a somewhat faster pace (4 h) [36]. Interestingly,
Palmer et al. were unable to demonstrate desensitization in
CHO cells expressing the human A1R[ 37]. Klaasse et al.,
however, were able to show internalization of the human
A1R tagged with a C-terminal yellow fluorescent protein
(hA1YFP-R), stably expressed in CHO cells. Exposure of
these cells for 16 h to 400 nM or 4 μM CPA resulted in 25
and 40% receptor internalization, respectively. Addition of
10 μM of the allosteric enhancer PD81,723 did not
accelerate the internalization process, but lowered the
threshold concentration at which internalization occurred.
Under those conditions a small degree of internalization
was observed already at a concentration of 40 nM CPA, and
at 400 nM CPA, 59% of the receptors internalized [38].
Exposure of cerebellar granule cells, endogenously
expressing A1R, to 100 nM R-PIA for 2–48 h led to a
blunting of the inhibition of adenylyl cyclase. Along with
this observation, a decrease of [
3H]cyclohexyladenosine
([
3H]CHA) binding to intact cerebellar granule cells and an
increase of [
3H]CHA binding in microsomes was detected.
Simultaneously, a decrease in the steady-state level of Gia
in plasma membrane and microsomes was observed. These
findings point not only to homologous desensitization, but
also to subsequent internalization of the A1Ri nt h e
microsomal fraction of cerebellar granule cells upon long-
term agonist exposure. However, no change in mRNA level
was observed, suggesting that post-transcriptional regula-
tion underlies receptor desensitization [39].
In hippocampal neurons, A1Rs are present on both
presynaptic and postsynaptic terminals, as well as on the
cell body and dendrites where they exert different actions.
To address the question of whether desensitization was
influenced by subcellular localization, neurons were ex-
posed to the agonist 2-chloroadenosine (CADO, 20 μM)
from 2 up to 96 h. It was found that upon agonist exposure
in cultured hippocampal neurons, the presynaptic A1Rs
desensitize less quickly (>12 h) than the postsynaptic A1Rs
(2 h). In accordance, the recovery of desensitized presyn-
aptic A1Rs also requires more time (48 h vs 8 h for
postsynaptic A1R). Desensitization of the postsynaptic
A1Rs apparently occurs at the level of the receptor, because
the other elements of the signal transduction machinery
appeared to be fully functional upon receptor desensitiza-
tion. All in all, these results suggest that the extent and the
kinetics of agonist-induced desensitization of A1Rs depend
on the subcellular localization of the receptors [40].
Using a more intact preparation, Coelho et al. found that
the density of A1R in rat hippocampal slices was decreased
by 30% upon 60 min of imposed hypoxia. This desensiti-
zation could be mimicked by adding the A1R agonist
CADO (10 μM) for 60 min and was prevented by adding
the A1R antagonist DPCPX. These results suggest that
hypoxia leads to an increase in extracellular adenosine
levels, and a subsequent, quite rapid (<90 min) desensiti-
zation, possibly followed by subsequent internalization of
the A1R in nerve terminals [41].
Rat in vivo studies also demonstrated A1R desensitiza-
tion. In a study by Parsons and Stiles rats were chronically
(6 days) infused with R-PIA. Examination of adipocyte
membranes of both treated and control rats revealed a 40%
lower inhibition of adenylyl cyclase in the treated animals,
coinciding with a reduced number of A1Rs (68% agonist-
occupied receptors remaining) as determined by radioligand
binding [42]. Upon further study it was noticed that the
effects on adenylyl cyclase were not A1R specific but were
controlled at the level of adipocyte G proteins. Gi levels
appeared downregulated, whereas the amount of Gs in the
preparation was increased, although not at the level of their
mRNA, suggesting a heterologous form of desensitization
[43].
Chronic exposure of rats to R-PIA (6 days) also led to
A1R desensitization in the brain, and subsequent reduced
inhibition of adenylyl cyclase. This loss of response was
accompanied by a significant decrease in both total
numbers of A1R and Gia proteins in synaptic plasma
membranes in the brain, paralleling the finding by Stiles
and co-workers in adipocytes [44]. As a consequence, a
significant increase of A1R was observed in microsomes
and coated vesicles, which suggested a role for coated
vesicles in the internalization of A1R. Similarly, chronic
agonist exposure of rats to NECA (6 days) resulted in a
significant decrease of A1R in the high-affinity state in the
rat brain, however without changes in adenylyl cyclase
activity or inhibition of the Gia proteins [45].
Molecular mechanisms
As discussed in the general introduction to this review,
receptor posttranslational modifications, receptor phosphor-
ylation, recruitment of arrestins and the formation of
clathrin-coated pits are elements of the molecular machin-
ery of desensitization and internalization. In addition, other
potential protein partners in the two processes have been
studied for the various adenosine receptor subtypes, which
will also be discussed.
Effect of receptor posttranslational modifications
on desensitization and/or internalization
Gao et al. studied the effects of preventing palmitoylation
of the A1R. It appeared that the Cys
309Ala mutation, thus
removing the palmitoylation site of the human A1R, had no
effect on internalization [46]. These findings were later
confirmed by Ferguson et al. [47].
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A1R phosphorylation by GRKs has been subject to debate.
Palmer et al. and Ferguson et al. failed to demonstrate
GRK-2 phosphorylation of A1R; in the latter study it was
found that nonphosphorylated A1R redistributes arrestin 3
from the cytoplasm into punctate clusters at the plasma
membrane [37, 47]. Nie et al., however, reported that within
1 h of exposure of DDT1MF-2 cells to R-PIA, rapid
translocation of GRKs was observed from the cytosol to the
cytoplasm [36]. In a further biochemical approach with
both purified receptor and GRK-2, a phosphorylated
receptor was obtained that showed enhanced affinity for
arrestins over G proteins. The same receptor kinase, upon
overexpression in FRTL-5 cells, influenced A1R signalling,
however, not via Gia-mediated adenylyl cyclase but
through Gibg-mediated MAP kinase activation [48]. It may
be concluded that under physiological conditions A1R
phosphorylation does not (readily) take place, which would
be a rationale for the long time periods required for receptor
internalization.
Other protein partners
The ectoenzyme adenosine deaminase (ADA) regulates the
extracellular adenosine concentration by converting excess
adenosine into inosine. However, ADA also plays a role in
the desensitization and internalization of A1R in smooth
muscle DDT1MF-2 cells [49, 50] and LLC-PK1 epithelial
cells [51], acting as a receptor activity-modifying protein
(RAMP). Upon agonist exposure (100 nM R-PIA, 2 h),
ADA and A1R formed complexes on the cell surface,
clustered and internalized together to intracellular compart-
ments. Such clustering of adenosine A1 receptors prior to
internalization was also reported by Ciruela et al. and Saura
et al. [49, 52]. The intracellular vesicles contained the lipid
raft marker protein caveolin. Filipin, an agent that disrupts
rafts or caveolae, inhibited A1R internalization. In contrast,
acidic treatment disrupting clathrin-coated vesicles did not
inhibit agonist-induced internalization of A1R. These
results indicate that ADA and A1R form a stable complex
in the cell membrane of LLC-PK1 cells, internalizing upon
agonist exposure via lipid rafts, in a clathrin-independent
pathway. Furthermore, a direct interaction of the C terminus
of A1R with caveolin was demonstrated [50]. These and
other data suggest that the mode of receptor compartmen-
talization in response to agonist stimulation may be
governed by both receptor subtype and cell type [51].
Another accessory protein, the heat shock cognate
protein 73 (hsc73), a member of the hsp70 family, was
identified as a cytosolic component able to interact with the
third intracellular loop of the A1R. The interaction between
hsc73 (30 nM) and A1R led to a marked reduction in
affinity of ligands for the A1R and also prevented activation
of the G proteins, even more so than the addition of GTP
analogues or GTP itself (100 μM). These effects were
completely prevented by the addition of 25 nM ADA. A
high percentage of A1R was coupled to hsc73 in cell lysate,
according to immunoprecipitation experiments. A remarkable
feature upon internalization of the receptor in DDT1MF-2
cells was found; A1Rs internalized via two different vesicle
types, one in which A1R and hsc73 are colocalized and
another in which hsc73 was absent. These observations open
the possibility that signalling via GPCRs is regulated at least
to some extent by heat shock proteins [53].
Receptor-receptor interactions
Dunwiddie et al. found that activation of A3Rw i t ha
selective A3R agonist resulted in subsequent heterologous
desensitization of the A1R, as observed in electrophysiolog-
ical experiments in the CA1 region of rat hippocampus.
Similar results were obtained after A3R occupancy via a brief
superfusion with a high concentration of adenosine [54].
Lopes et al. investigated how activated A2AR influenced
A1R function and whether this interaction was modified in
aged rats. In hippocampal and cortical nerve terminals, the
A2AR agonist CGS 21680 (30 nM) was able to lower the
binding affinity of the A1R-selective agonist CPA, and this
was taken as proof for A1R desensitization. The effect was
counteracted by the addition of the A2AR antagonist ZM
241385 (20 nM). This reduction in A1R function could only
be detected in young adult rats (6 weeks), but not in old rats
(24 months). The addition of a PKC inhibitor, chelerythrine
(6 μM), also prevented the desensitization of A1R[ 55].
S i m i l a r l y ,C i r u e l ae ta l .[ 56] demonstrated that A1R-A2AR
heteromers were able to modulate the glutamatergic neuro-
transmission in the rat striatum. The main biochemical
characteristic of this heteromer is the ability of the agonist-
occupied A2AR to reduce the agonist affinity of the A1R[ 56].
By binding to cannabinoid CB1 receptors in Purkinje
fibers in the cerebellum, Δ
9-tetrahydrocannabinol inhibits
adenylyl cyclase and consequently motor coordination.
Long-term Δ
9-tetrahydrocannabinol treatment resulted in
CB1R downregulation, desensitization of the Gia protein
and desensitization of adenylyl cyclase. G protein activa-
tion by A1R, however, was unaffected. Surprisingly,
heterologous attenuation of A1R-mediated inhibition of
adenylyl cyclase was observed. These results indicate that
long-term Δ
9-tetrahydrocannabinol administration produ-
ces a disruption of inhibitory receptor control of cerebellar
adenylyl cyclase and suggest a potential mechanism of
cross-tolerance to the motor effects of cannabinoid and A1
agonists [57].
D1R and A1R have been shown to form functionally
interacting heteromeric complexes in engineered cell lines
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agonist caused complex formation of both receptors.
Combined pretreatment with selective agonists for both
receptors (but not one agonist alone) substantially reduced
cAMP accumulation induced via the D1R, indicative for
this receptor’s desensitization [58].
A2A receptor
Cellular and physiological studies
DDT1 MF-2 cells, expressing both A1R and A2AR, were
exposed to an A2A-selective agonist, which resulted in a
rapid loss (t1/2=45 min) of agonist-stimulated cAMP
production in these cells. This receptor desensitization,
however, did not involve a reduction in cell membrane
receptor number or a change in ligand affinity [35].
Prolonged exposure of PC12 cells, expressing both
A2AR and A2BR, to AR agonists led to a fast (30 min)
and significant inhibition of A2AR stimulation by the A2AR-
selective agonist CGS21680. This effect appeared to occur
at the level of adenylyl cyclase, since no change was
observed in receptor number or in CGS21680’s affinity for
the receptor. This conclusion was corroborated by the
finding of reduced activation of adenylyl cyclase by
forskolin. Longer agonist exposure (12–20 h) led to a
reduction of Gsa levels, whereas no changes occurred in the
short-term protocol [59].
NG108-15 neuroblastoma x glioma hybrid cells express
both A2ARa n dA 2BR[ 60, 61]. Treatment of the cells with
the non-selective agonist NECA followed by its washout led
to a rapid (t1/2=20 min) and pronounced reduction in cAMP
production by the A2AR-selective agonist CGS21680 when
compared to vehicle-treated cells.
Palmer et al. [62] generated CHO cells solely expressing
the recombinant (canine) A2AR and examined the desensi-
tization process of this receptor. Cells exposed to NECA
showed a rapid desensitization of A2AR-stimulated adenylyl
cyclase activity with no obvious difference between pretreat-
ment of 30 min or 24 h. This was associated with a slightly
reduced affinity of the receptor for the A2AR-selective
radiolabelled agonist [
3H]CGS21680. Cell surface receptor
numbers only diminished significantly (up to 40%) upon
longer-term pretreatment (t1/2=8 h) [62].
Using a tissue preparation, Conti et al. investigated
whether prolonged exposure of A2AR to the non-selective
agonist NECA, or to the selective A2ARa g o n i s t sC G S 2 1 6 8 0
and 2HE-NECA, influenced A2AR desensitization. The
authors used the porcine coronary artery as a sensitive
vascular model, expressing among others A2ARs. The
arteries were first precontracted by adding 3 μMP G F α.
NECA, CGS21680 and 2HE-NECA showed high affinities
for the A2AR( E C 50’s of 72, 40 and 20 nM, respectively)
inducing vasorelaxation. Next, coronary arteries were pre-
treated with 10 μM NECA for 30 min or 2 h. After a 2-h
washout period, the functional response was assessed. It
appeared that preincubation with NECA did not hamper the
vasorelaxing effects of CGS21680 and 2HE-NECA. How-
ever, NECA response curves were shifted to the right after
NECA pretreatment [63]. These results seem inconclusive,
since NECA pretreatment might ‘hit’ other adenosine
receptor subtypes.
A2ARs, next to A1R, are present on presynaptic
baroreceptor afferent terminals within the nucleus tractus
solitarius (NTS) in the brain [64]. It was observed that these
A2AR modulate 5-HT release as a mechanism of baroreflex
control mediated by the NTS. Low concentrations of the
non-selective agonist NECA (0.3–3 nM), briefly exposed
(5 min) to NTS brain slices, induced the release of 5-HT
caused by the activation of the A2AR present at presynaptic
nerves. This effect could be blocked by the addition of the
adenosine A2AR antagonist 8-(3-chlorostyryl)caffeine
(CSC; 100 nM). Longer exposure of NECA (20 min) to
the NTS slices resulted in inhibition of the 5-HT release,
probably caused by quick desensitization of the A2AR
(15 min) and subsequent involvement of the A1R[ 65].
These findings were corroborated in a similar study with
CGS21680, an A2AR-selective agonist [66].
The effects on AR fate upon chronic agonist exposure
were studied in vivo in rat brain [45]. After 6 days of
NECA treatment, the adenylyl cyclase activity in synaptic
plasma membranes was decreased, suggesting a desensiti-
zation of A2Rs, although the authors did not specify or
study which A2R subtype was involved. Gs protein levels
were decreased indicating Gs downregulation as the
mechanism of desensitization.
Interestingly, Rekik and Mustafa [67] showed that
chronic antagonist treatment (3 days) of porcine coronary
arteries with ZM241,385 led to a decreased agonist
responsiveness. Although A2A receptor expression went
up, it appeared that the levels of Gs had decreased, al-
together leading to a functional desensitization of the
relaxing response by e.g. CGS21680 [67]. It should be
kept in mind that ZM241,385 is also a potent antagonist for
the adenosine A2B receptor.
Molecular mechanisms
Effect of receptor C terminus on desensitization
and/or internalization
To investigate the importance of the (120 amino acid
residues) long C terminus of the A2AR receptor in inducing
desensitization and internalization, Palmer and Stiles
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tail. It appeared that deletion of the last 95 amino acids of
the C terminus, containing 10 possible phosphorylation
sites, did not have any effect on radioligand binding,
adenylyl cyclase activity or desensitization kinetics com-
pared to the wild-type A2AR. However, when two possible
phosphorylation sites (Thr 298 and Ser 305) just upstream
the 95 deleted amino acids were mutated to Ala, short-term
(30 min) agonist-induced desensitization was attenuated,
while the long-term (24 h) desensitization was not affected.
Single mutations revealed that mutation of Thr 298 alone
was sufficient to reduce receptor phosphorylation and
agonist-induced short-term desensitization. This study also
shows that short-term and long-term desensitization have
distinct structural requirements and do not occur via the
same mechanism [4].
GRKs and arrestins
Which GRK isoforms are involved in the phosphorylation
of the A2AR is not entirely clear yet. However, a putative
role for GRK2 and/or GRK5 has been suggested [4]. The
role of GRK2 in agonist-induced phosphorylation and
subsequent desensitization of A2AR and A2BR was thor-
oughly investigated by Kelly and co-workers. Wild-type
GRK2 was stably expressed in NG108-15 cells, which
endogenously express A2AR and A2BR. The acute stimula-
tion of adenylyl cyclase by activation of A2ARw a s
markedly reduced in NG108-15 cells overexpressing wild-
type GRK2. This was probably caused by GRK2-dependent
pre-desensitization of the A2AR by extracellular adenosine.
This effect could be reversed by pretreating the cells 24 h
with 0.5 unit/ml ADA [68]. The same research group
investigated the effect of a dominant-negative GRK2
mutant on the desensitization of the A2AR[ 60]. Stable
transfection of a GRK2Lys220Arg mutant in NG108-15
cells reduced desensitization of the A2AR by 50% following
a 30-min treatment with the adenosine agonist NECA.
Tumour necrosis factor (TNF)-α treatment of human
monocytoid THP-1 cells expressing the A2AR prevented
desensitization of this receptor, occurring under control
conditions upon pretreatment with CGS21680 or NECA
[69]. It was discovered that the TNF-α treatment prevented
GRK2 translocation to and decreased GRK2 association
with the plasma membranes of these cells as a consequence
of the activation of a sphingomyelinase-dependent pathway.
In another study, Mundell and Kelly investigated the
effect of inhibitors of receptor internalization on desensiti-
zation and resensitization of ARs in NG108-15 cells [70].
Before agonist exposure, cells were pretreated with hyper-
tonic sucrose or concanavalin A (ConA), both inhibitors of
internalization. This pretreatment did not affect the agonist-
induced desensitization of the A2AR. However, the resensi-
tization of the A2AR upon agonist removal was abolished in
the presence of ConA or sucrose.
Arrestins 2 and 3 have been implicated in the down-
stream desensitization process. CGS21680 stimulation of a
tagged A2AR transiently transfected in HEK293 cells
induced the translocation of GFP-tagged arrestins 2 and 3
towards the plasma membrane. A dominant-negative
arrestin 2 mutant inhibited agonist-induced internalization
[71].
Other protein partners
The long C terminus of the A2AR has been coined a
‘coincidence detector’ as it recognizes quite a number of
other proteins such as α-actinin and ARNO, the Arf
nucleotide site opener (for a review see Gsandtner and
Freissmuth [72]). α-Actinin may play a role in receptor
internalization, not unlikely for a protein involved in cyto-
skeletal arrangements [71], however ARNO does not [73].
Receptor-receptor interactions
The A2AR colocalizes with D2 dopamine receptors in the
basal ganglia, and their interaction has been documented on
several occasions [74]. For instance, the protein-protein
interaction between A2AR-D2R was confirmed in
HEK293T cells. The most likely mode of interaction is
that helix 5 and/or helix 6 and the N-terminal portion of I3
in the D2R approach helix 4 and the C terminus of the
A2AR[ 75]. Within the scope of this review fits the
observation that activation of the D2 receptor actually
sensitizes A2AR-mediated increases in cAMP production, in
CHO cells expressing both receptors [76] as well as in
CAD and NS20Y neuroblastoma cells in which the D2
receptor was expressed [77]. In SH-SY5Y neuroblastoma
cells co-stimulation of A2AR and D2R accelerated D2R
desensitization, probably by causing or enhancing D2R
internalization [78]. Recently it was found that in these SH-
SY5Y neuroblastoma cells the A2AR also formed hetero-
mers with the endogenously expressed CB1R. The CB1Ri s
negatively coupled to adenylyl cyclase and requires
previous or simultaneous activation of A2AR to signal in
these cells [79].
A2B receptor
Cellular and physiological studies
The adenosine A2B receptor (A2BR) is endogenously
expressed on most artificial cell lines, such as COS and
HEK293 cells. The exception is formed by CHO cells that
lack this adenosine receptor subtype.
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subtypes, is subject to agonist-induced desensitization. This
was measured on the level of cAMP production by Peters
et al. [80]. Pretreatment of COS7 cells endogenously
expressing A2B receptors with the non-selective agonist
NECA (1 μM) for 1 up to 17 h led to a significant reduction
in cAMP production upon acute agonist challenge, already
after 1 h of pretreatment. Maximal reduction of cAMP
production was reached after 4 h of pretreatment. CHO
cells stably expressing a 5′ FLAG epitope-tagged A2B
receptor showed the same result, albeit that maximal
reduction of cAMP response was already achieved after
1 h of pretreatment. Also mouse 3T3-L1 cells and human
HEK293 cells, endogenously expressing the A2BR, showed
a decreased cAMP response after 2 h and 5.5 h of
pretreatment with 1 μM NECA, respectively [80]. In
NG108-15 cells, expressing both A2ARa n dA 2BR, the rate
of desensitization for both receptor subtypes appeared
similar, with a half-life of 15–20 min. Pretreatment with
NECA of these cells (0.1 mM, 30 min) reduced stimulation of
adenylyl cyclase by A2BR by approximately 50% [60, 61].
Rat pheochromocytoma PC12 cells also endogenously
express both A2AR and A2BR. Prolonged exposure (14 h) to
100 nM NECA or 1 μM CGS21680 significantly inhibited
the cAMP response of the cells to subsequent stimulation
with the A2A-selective agonist CGS21680. Although a 100-
fold higher NECA concentration is needed to stimulate the
A2BR compared to A2AR, Chern et al. found that the A2B
receptor cAMP response was also desensitized upon
desensitization of the A2A receptor. This observation can
be explained by the fact that the Gsa protein level and the
adenylyl cyclase activity were diminished upon long-term
desensitization of the A2AR by CGS21680 [59].
The domain in which the receptor resides is also
important for desensitization events, according to Sitaraman
et al. NECA (10 μM) added to either the apical or
basolateral side of T84 intestinal cells resulted in desensi-
tization of the A2BR on the corresponding side within 2–
3 h. However, whereas applying NECA to the apical side of
the membrane had no effect on the basolateral A2BR,
basolateral NECA induced a complete desensitization of the
apical receptor. Since receptor trafficking may play a role in
this cross-desensitization process, this effect may contribute
to the desensitization and subsequent downregulation of the
A2BR[ 81].
Trincavelli et al. observed a very rapid desensitization
(t1/2=5 min) of A2BR in a human astrocytoma cell line.
Both G protein coupling efficiency and cAMP production
were diminished after pretreatment of the cells with NECA
in the presence of an A2AR-selective antagonist [82].
Mundell et al. reported that acute exposure of human
airway smooth muscle (ASM) cells to adenosine receptor
agonists resulted in a rapid accumulation of cAMP, most
probably via A2BR. Treatment with adenosine deaminase
(ADA) suggested that ASM cells produce adenosine which
feeds back on the cells’ A2BRs, thereby regulating basal
cAMP levels and inducing a small degree of A2BR
desensitization. Chronic treatment with adenosine agonists
had a dual effect; both A2BR desensitization and adenylyl
cyclase sensitization (an increased responsiveness of
adenylyl cyclase upon stimulation) were observed [83].
Haynes et al. [84] studied A2BR desensitization in both
pulmonary artery smooth muscle cells and a more integrat-
ed preparation, the isolated perfused lung. Pretreatment of
the smooth muscle cells with NECA for 45 min abrogated
the increase in cAMP response otherwise observed for both
NECA and isoproterenol, suggesting heterologous desensi-
tization. Indeed, experiments with cholera toxin showed
that the desensitization took place at the level of the Gs
protein-adenylyl cyclase complex. In the lung preparation
NECA, when dosed acutely, caused a rapid vasodilation,
which was not observed when the tissue was treated again
with the same compound 45 min after the first dose [84].
Taken together, these results suggest that desensitization
of the A2B receptor is a robust phenomenon, rather
independent from the cell type or tissue in which it is
expressed.
Molecular mechanisms
Effects of receptor mutations on desensitization
and/or internalization
Matharu et al. studied the regions of the A2BR which are
responsible for the desensitization and internalization of the
A2BR[ 85]. For this purpose they introduced point
mutations or deletions in the C terminus of the A2BR.
Deleting the final two amino acids (Leu
330-stop) did not
affect the internalization properties of the A2BR. The
Phe
328-stop and Gln
325-stop mutants, however, were resis-
tant to agonist-induced desensitization and internalization.
GFP-tagged arrestin 2 did not translocate from the cytosol
to the plasma membrane upon agonist stimulation of these
two truncated receptors. From a single point mutation in the
C terminus, Ser
329Gly, it became clear that this serine
residue is responsible for the rapid agonist-induced desensi-
tization and internalization. Surprisingly, a further deletion
mutant Ser
326-stop was able to undergo rapid agonist-
induced desensitization and internalization; however,
arrestin 2 was not attracted to the plasma membrane upon
agonist stimulation. It appeared that internalization of this
truncated receptor occurred via an arrestin- and clathrin-
independent pathway, probably via caveolin-mediated
internalization since the internalization of Ser
326-stop was
dynamin dependent. The destination of this truncated
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plasma membrane, instead of early endosomes. Whether the
receptor will undergo rapid agonist-induced desensitization
and internalization or influence the rate, extent and
mechanism of internalization depends on specific sites in
the C terminus of the A2BR and can be influenced by their
mutation or deletion.
GRKs and arrestins
The A2BR, endogenously expressed in NG108-15 cells, is
desensitized through phosphorylation by GRK2. This
GRK2 effect was selective for A2ARa n dA 2BR, since the
other endogenously expressed receptors (secretin R and IP-
prostanoid R) were not desensitized in this way [68]. In
addition, stable transfection of a dominant negative GRK2
(Lys220Arg) mutant in the NG108-15 cells reduced the
NECA-induced (30 min, 100 μM) desensitization of the
A2BRb y5 0 %[ 60]. Peters et al. studied the role of
phosphorylation by PKA and PKC rather than GRK2 in
agonist-induced desensitization in COS-7 cells transiently
expressing the 5′-FLAG A2BR. They concluded that these
second messenger-dependent kinases are not involved in
A2BR phosphorylation [80]. A similar conclusion for A2BR
phosphorylation in NG108-15 cells was reached by
Mundell and Kelly [61]. Trincavelli et al. found that
treatment of astrocytoma cells with TNF-α increased the
A2BR functional response, without changing receptor
protein or mRNA levels. TNF-α treatment appeared to
markedly reduce agonist-dependent receptor phosphoryla-
tion and also attenuated agonist-mediated A2BR desensiti-
zation. These effects could be inhibited by the addition of
the A2BR antagonist MRS 1706 [82]. These findings
resemble data obtained with the A2AR (vide supra).
Mundell et al. found that within the arrestin family, both
arrestin 2 and arrestin 3 are involved in the internalization
process of the A2B receptor. Within 1 min of agonist
exposure, both GFP-tagged arrestin isoforms were trans-
located to the plasma membrane. Longer agonist exposure
(>10 min), however, revealed that only arrestin 2 colo-
calizes with the receptor in the early endosomes. One
explanation for this may be a higher affinity of the A2BR
for arrestin 2 compared to arrestin 3. Interestingly, arrestins
are not only involved in the internalization of the A2B
receptor, but also in its recycling. It appeared that the
expression of stable arrestin anti-sense constructs, reducing
the levels of endogenous arrestins, not only resulted in less
internalization of the receptors, but also impaired the
recycling process significantly. In contrast to the internal-
ization process, arrestin 3 induced a significantly faster rate
of A2BR recycling compared to arrestin 2 [86].
Penn et al. also studied the behaviour of GFP-tagged
arrestins, now in human airway smooth muscle cells.
Arrestin 2 and arrestin 3 were able to reduce the cAMP
production upon stimulation of endogenous A2BRb y
NECA and stimulation of β2-AR by isoproterenol. In
addition, a punctate clustering was observed in the
membrane upon exposure to either NECA (100 μM) or
isoproterenol (1 μM), indicating that arrestins play a role in
receptor trafficking. On the contrary, signalling and
trafficking of the prostaglandin E2-R, another endogenously
expressed receptor, was not affected by arrestin 2 or arrestin
3[ 27].
A3 receptor
Adenosine A3 receptors (A3R) evoke considerable interest
as novel drug targets to address cerebral/cardiac ischaemia,
cancer, inflammation, asthma and chronic obstructive
pulmonary disease. So far, potent and selective antagonists
for the hA3R have been identified; the disadvantage
however is that those antagonists show extremely low
binding affinity for the rodent A3R, typically 1,000 times
lower than in humans. Since rodent models are essential for
the pharmacological evaluation of new therapeutic agents,
this forms a serious drawback.
In addition, the adenosine A3 receptor (A3R) sequence
holds a nuclear localization signal in its C-terminal tail [87].
This typical stretch of four amino acids (KKFK) in helix
8 may direct the receptor to the cell nucleus, not necessarily
as a consequence of desensitization or internalization. This
should be kept in mind when appreciating the studies
described below.
Cellular and physiological studies
Ramkumar et al. studied the characteristics of rat A3R,
endogenously expressed on RBL-2H3 mast cells. In one of
their experiments the authors pretreated the cells with
NECA and found a partial desensitization of the initial Ca
2+
response to NECA [88]. Trincavelli et al. studied the
relationship between agonist-induced desensitization, inter-
nalization and resensitization of hA3R in transfected CHO
cells. Agonist-induced endocytosis of hA3R was investi-
gated by immunogold electron microscopy of plasma
membranes and intracellular vesicles and shown to occur
with a half-life of 17 min. Subsequent removal of the
agonist led to recycling of 90% of the receptor population
to the cell surface, with a half-life of 35 min. Short-term
exposure to agonist caused rapid desensitization, as
assessed in cAMP assays. Removal of the agonist led to
resensitization of the cAMP signal to 90% of the original
signal within 120 min. Internalization did not affect signal
transduction, as was demonstrated after blockade of
internalization and recycling. Internalization occurred via
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goes agonist-induced endocytosis, which is not responsible
for desensitization. Moreover, in the case of hA3R, receptor
sequestration rather than desensitization seems to be the
first step in a cycle of internalization, dephosphorylation
and recycling to the plasma membrane [89]. A similar cell
line was used by Palmer et al. In stably transfected CHO
cells prolonged treatment with NECA (10 μM, 20 h)
induced uncoupling of recombinant hA3R from Gi proteins
and a functional desensitization. Upon this A3R desensiti-
zation, an approximately twofold increase in adenylyl
cyclase activity was found in the presence or absence of
forskolin. This sensitization of adenylyl cyclase activity
w a sn o tc a u s e db ya na l t e r e dl e v e lo fi n h i b i t o r yo r
stimulatory G protein expression. The occurrence of the
sensitization was also not due to new protein synthesis, but
probably to an increased coupling efficiency between Gs
and adenylyl cyclase. Compared to control cells, long-term
exposure of stably transfected CHO cells to NECA caused
an increase in phosphorylation of the cAMP-responsive
element binding protein upon addition of suboptimal
concentrations of forskolin. The sensitization of adenylyl
cyclase activity upon long-term treatment might provide a
molecular basis for the observation that for several
adenosine receptor-mediated events, acute agonist exposure
produces opposite effects to those after chronic agonist
treatment [90]. Ferguson et al. studied the fate of the rat
A3R expressed in CHO cells. The receptors internalized
rapidly after treatment with NECA or R-PIA over a time
frame (t½=10 min) that followed receptor phosphorylation
(t½=1 min) [91].
The desensitization, internalization and downregulation
of hA3R was also investigated in human astrocytoma cells,
natively expressing hA3R. Short-term (15 min) exposure of
the cells to 100 nM Cl-IBMECA, an A3R-selective agonist,
caused rapid receptor desensitization, subsequently fol-
lowed by receptor internalization within 30 min. With the
help of immunogold electron microscopy, the localization
of the A3R was revealed. After 10 min of exposure, the
A3R was found in smooth-surfaced pits and in uncoated
vesicles in the cytoplasm. After 30 min of exposure, the
A3R was found in vesicular endosomes. Upon removal of
the agonist, resensitization of the A3R occurred within
120 min through receptor recycling to the cell surface.
Long-term agonist exposure (1–24 h) resulted in a marked
downregulation of A3R to 22±3% of control after 24 h. In
conclusion, multiple, temporally distinct and sequential
processes are involved in the regulation of hA3R upon
short- and long-term exposure to agonists [92].
A3Rs were found to be highly expressed on murine B16-
F10 melanoma cells [93]. The authors examined the
association between A3R trafficking and receptor function-
ality and tumour growth inhibition upon activation with the
A3R-selective agonist IB-MECA. Exposure to 10 nM IB-
MECA (5 min) led to rapid internalization of A3R to the
cytosol, upon which receptors were directed to the endo-
somes for recycling or to lysosomes for degradation. The
addition of 100 nM MRS 1523 (5 min), an A3R antagonist,
was able to counteract the internalization process as well as
the modulation of the Wnt pathway leading to proliferation,
thereby emphasizing the involvement of A3Ri nt h i s
process. When the melanoma cells were injected into nude
mice, tumours rapidly developed. Tumour growth was
significantly inhibited after administration of IB-MECA to
the animals, paralleled by a decrease in A3R expression in
tumour lesions. In hypoxic human A172 and U87MG
glioblastoma cell lines it was found that adenosine
upregulates the expression of hypoxia-inducible factor-1α
(HIF-1α) and vascular endothelial growth factor (VEGF)
via the A3 receptor. HIF-1α is a key regulator in the
development of tumours. The addition of the A3-antagonist
MRE 3008F20 inhibited the adenosine-induced HIF-1α
and VEGF accumulation in these hypoxic cells, thereby
showing a putative role in inhibiting tumour growth [94].
To circumvent the species differences mentioned in the
introduction to the A3R section, Yamano et al. generated
A3R humanized (A3AR
h/h) mice in which the A3R was
replaced by its human counterpart. The expression level of
hA3R in the humanized (A3AR
h/h) mice was equal to the
expression levels of A3R in wild-type mice. A3R agonists
were able to elevate the intracellular Ca
2+ concentration in
bone marrow-derived mast cells from the humanized
(A3AR
h/h) mice. However, the rate of hA3R internalization
was markedly reduced compared with that of mA3Ri n
these mast cells [95].
Molecular mechanisms
Receptor phosphorylation, GRKs and arrestins
Palmer and Stiles as well as Ferguson et al. investigated
which amino acid residues in the C terminus are responsible
and crucial for the rapid desensitization of the A3R[ 96, 91].
A triple mutant (Thr
307, Thr
318 and Thr
319 to Ala) exhibited
dramatically reduced phosphorylation, desensitization and
internalization of the rat A3AR. Individual mutation of each
Thr residue showed that Thr
318 and Thr
319 were the most
important sites for phosphorylation. In addition, phosphor-
ylation of Thr
318 was necessary to observe phosphorylation
of Thr
319, but not vice versa. Moreover, changing Thr
318
for a negatively charged residue (Glu) was not sufficient to
retain phosphorylation at Thr
319. Mutating two predicted
palmitoylation sites, Cys
302,305 to Ala resulted in agonist-
independent basal phosphorylation of the rat A3AR. Such
findings strongly suggest that palmitoylation of these Cys
Purinergic Signalling (2008) 4:21–37 33residues is an important factor in controlling accessibility of
the C terminus of the A3R in the process of recruiting
GRKs. In fact, the palmitoylation sites are highly conserved
between different species, e.g. rat, mouse, human, dog,
sheep. Taking these results together, it appears that GRK-
mediated phosphorylation of the A3R C terminus follows a
sequential mechanism, with the receptor palmitoyl moieties
in an important regulatory role, and phosphorylation of
Thr
318 being particularly crucial as an essential first step. In
an earlier study Palmer et al. replaced the carboxyl terminus
of the A1R by that of the A3R[ 37]. This chimaeric
construct was able to undergo agonist-stimulated phosphor-
ylation and functional desensitization, similar to A3R. It
was also found that purified GRK2, GRK3 and GRK5 were
all able to enhance agonist-dependent phosphorylation of
A3R as well as the A1-A3 chimaera.
Trincavelli et al. studied the involvement of extracellu-
larly regulated kinases (ERK1 and 2), members of the
mitogen-activated protein kinase (MAPK) family, in A3R
phosphorylation. It was found that within 5 min of
exposure to 10 μM NECA, ERK1 and 2 were already
phosphorylated in CHO cells stably expressing hA3R. An
inhibitor of MAPK activation (PD98059) also caused
inhibition of A3R phosphorylation, desensitization and
internalization, probably by preventing the membrane
translocation of GRK2. These results indicate that the
MAPK cascade is involved in A3R regulation by a
feedback mechanism which controls GRK2 activity and
probably involves direct receptor phosphorylation [97].
The rat basophilic leukaemia cell 2H3 cell line (RBL-
2H3 cells) endogenously expresses equal levels of arrestin
2 and arrestin 3. Both arrestin isoforms also have a high and
comparable affinity for clathrin, thereby promoting agonist-
induced internalization. RBL-2H3 cells also endogenously
express a high level of A3R, which, however, neither
recruited arrestin 3 nor arrestin 2 upon stimulation with
NECA. Also no changes in A3R distribution were ob-
served. One explanation is that A3R follows an endocytic
mechanism upon agonist stimulation that does not involve
arrestin-mediated clathrin-coated pit internalization. Anoth-
er possible explanation is that arrestin recruitment was
below the limit of detection in the RBL-2H3 cells [98].
Ferguson et al. observed that upon phosphorylation of A3R
by GRK arrestin 3 is redistributed into punctate vesicles
both at the plasma membrane and within the cytoplasm.
Nevertheless, these authors also noticed that there was no
colocalization between A3R and arrestin 3 [47].
Conclusions
The adenosine receptor subtypes are differentially regulated
when exposed to agonist treatment. A1Rs are not (readily)
phosphorylated and slowly internalize with a typical half-
life of several hours. This feature may cause less than
average tachyphylaxis upon chronic agonist administration,
for instance in type II diabetes. A2AR and A2BR show much
faster downregulation with similar kinetics, usually < 1 h
for short-term desensitization. Agonists for the A2A
receptor, currently profiled in wound healing, may thus
suffer from declining efficacy upon chronic administration,
in contrast to those for the A1 receptor. The A3R undergoes
even faster downregulation, often a matter of minutes. The
latter receptor also holds a nuclear localization signal in its
carboxy terminal tail, possibly obscuring true agonist-
induced downregulation. The fast desensitization of the
A3R after agonist exposure may be therapeutically equiv-
alent to antagonist occupancy of the receptor.
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